Letter to the Editor: Are We Asking the Right Question for New Biomarkers – “Ready for Prime Time” Versus Demonstrated Clinical Utility?

Authors:
Grace Y. Kim Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Search for other papers by Grace Y. Kim in
Current site
Google Scholar
PubMed Close
 MD
,
Jeanne Tie Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Search for other papers by Jeanne Tie in
Current site
Google Scholar
PubMed Close
 MBChB, MD
, and
Peter Gibbs Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Department of Medical Oncology, Western Health, Victoria, Australia

Search for other papers by Peter Gibbs in
Current site
Google Scholar
PubMed Close
 MBBS, MD
Volume/Issue:
Volume 23: Issue 5
Online Publication Date:
May 2025
DOI:
https://doi.org/10.6004/jnccn.2025.7037
Restricted access
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Caughey BA, Parikh AR. ctDNA/MRD testing for colon cancer: a work in progress or ready for prime-time standard of care? J Natl Compr Canc Netw 2024;22:e247049.

  • 2.

    Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi64–72.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Tie J, Wang Y, Lo SN, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year updated analysis of the randomised DYNAMIC trial. Nat Med. Published online March 7, 2025. doi:10.1038/s41591-025-03579-w

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29:127–134.

  • 6.

    Li Y, Heer AK, Sloane HS, et al. Budget impact analysis of circulating tumor DNA testing for colon cancer in commercial health and Medicare Advantage plans. JAMA Health Forum 2024;5:e241270.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Lonardi S, Pietrantonio F, Tarazona Llavero N, et al. The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. Ann Oncol 2023;34(Suppl 2):S1268–1269. Abstract LBA28.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2025 by the National Comprehensive Cancer Network 2025
Article Category:
Letter
Print Publication Date:
01 May 2025
Online Publication Date:
May 2025

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 159 159 159
PDF Downloads 76 76 76
EPUB Downloads 0 0 0